Status:
UNKNOWN
Integrating Molecular, Genomic, Morphology and Environmental Features to Improve Precision Diagnosis and Treatment in Interstitial Lung Diseases (PRECISION-ILD)
Lead Sponsor:
Institut d'Investigació Biomèdica de Bellvitge
Conditions:
Interstitial Lung Disease
Interstitial Fibrosis
Eligibility:
All Genders
Brief Summary
Integrating Molecular, Genomic, Morphology and Environmental Features to Improve Precision Diagnosis and Treatment in Interstitial Lung Diseases (PRECISION-ILD) Background: Interstitial Lung Diseases...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age \> 18 years
- Signed informed consent
- Diagnosis of fibrotic ILD of any type in the 12 months prior to inclusion.
- Radiologic fibrotic changes of at least 5% on chest CT scan
- Ability to comply with the study protocol (in the opinion of the investigator)
- Ability to understand the information given and to sign the informed consent form.
- Exclusion Criteria
- Severe, advanced stage or life-limiting chronic diseases prior to the diagnosis of fibrotic ILD, or that represent a high risk of death in the short term (one year after inclusion), such as could be metastatic oncological metastatic diseases, advanced dementia, neurodegenerative diseases in a limiting phase.
- Pregnancy or breastfeeding
- Inability to complete required visits.
Exclusion
Key Trial Info
Start Date :
July 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05998512
Start Date
July 10 2023
End Date
December 31 2025
Last Update
August 21 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
2
Hospital La Princesa
Madrid, Spain
3
Hospital Virgen del Rocío
Seville, Spain